CanThera Biosciences

Canthera Discovery is a premier Australian drug discovery and development company focused on translating breakthrough academic research into novel cancer treatments. Formerly known as Cancer Therapeutics CRC (CTx), the company operates a sophisticated small molecule discovery platform that integrates high-throughput screening, medicinal chemistry, and lead optimization. Their business model centers on identifying high-value oncology targets and progressing them to clinical proof-of-concept before establishing strategic partnerships with global pharmaceutical companies. Notable achievements include the licensing of PRMT5 inhibitors to GSK and KAT6 inhibitors to Pfizer, both of which have progressed into clinical trials. The company maintains strong ties with leading Australian research institutes, ensuring a steady pipeline of innovative therapeutic candidates. Canthera Discovery is dedicated to addressing unmet needs in oncology and hematology through precision medicine approaches.